London, United Kingdom (CU)_ In a modest laboratory research, Johnson & Johnson said that the company’s single-dose COVID-19 vaccine demonstrated promising evidence of protection against the deadly Delta strain which is rapidly spreading in the US and other nations. According to the findings, the single-shot vaccine generated neutralising antibody activity against the Delta variant at an even stronger rate than what was recently found for the Beta (B.1.351) variant in South Africa.
The company’s statement said that the vaccine had…
